7th Cell Therapy Analytical Development Summit

With robust, reliable and regulatory-ready analytics lying at the heart of clinically successful cell therapies, now is the time to elevate your current workflows and strategies to prepare for clinical and commercial readiness.

Remaining the industry’s leading forum for cell therapy analytical, quality control, assay, and CMC professionals, the 7th Cell Therapy Analytical Development Summit will delve into cutting-edge technologies and proven strategies to aid you in demonstrating product safety, functionality, and quality before heading to market.

Focus your learning and address your specific needs with our refined two-track format, covering early- to late-stage assay development. No matter where you are in the product development cycle, gain hands-on expertise from designing predictive potency assays, through to validating and transferring methods for late-phase trials.

Featuring first-hand case studies and experiences from Takeda, Arsenal Bio, Bayer, Genentech, Adicet Bio, Quell Therapeutics, and the National Institute of Health, seize the opportunity to benchmark against peers, exchange solutions to persistent challenges, and strengthen your analytical toolkit, to excel in an increasingly competitive cell therapy landscape.


URLs:
Website: https://go.evvnt.com/3185582-0?pid=2874
Brochure: https://go.evvnt.com/3185582-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Solution Provider Pricing | Conference + Workshop Day: USD 5097.00,
Solution Provider Pricing | Conference Only: USD 3699.00,
Drug Developer Pricing | Conference + Workshop Day: USD 4197.00,
Drug Developer Pricing | Conference Only: USD 2999.00,
Academic Pricing | Conference + Workshop Day: USD 3597.00,
Academic Pricing | Conference Only: USD 2599.00

Speakers: Benjamin Espen | Principal Quality Engineer | Avobis Bio, Hadar Adams | Director, Analytical Development and Quality Control | Independent Expert, José Peña | Principal Scientist | Arsenal Bio, Laura Pierce | Biomedical Engineer | National Institute of Standards and Technology (NIST), Stephan Krause | Executive Director - Analytical Science and Technology, Cell Therapy Quality | Bristol Myers Squibb, Suning Wang | Senior Scientist | Vertex Pharmaceuticals, Ajen Prasad | AD, QC | BioNTech, Anna Lau | Chief, Sterility Testing Service | National Institute of Health Science, Betsy Rezner | Executive Director - Quality Control and Analytical Development | Fate Therapeutics, Christian Aguilera-Sandoval | Founder | SuperNova FlowCytometry, Divya Lenkala | Group Leader -DPCAD and T Cell Immunology | Formerly BioNTech, Fabian Zanella | Head of Analytical Development and Testing | Genentech, Haiyan Liu Senior | Director - Quality Control | Obsidian Therapeutics, Hiroshi Sugimoto | Director | Takeda Pharmaceutical, Kathryn Simon | Vice President Global Quality | Cellectis Stem Cells, Lynne Ensor | President | Independent Expert, Michael Zeng | Senior Manager | Vertex Pharmaceuticals, Nadia Ward Business | Development Manager | bioMérieux, Rebecca Malott | Quality Control Lead | University of Calgary, Rebecca Moore | Associate Director, Analytical Development | Quell Therapeutics, Shetty Ravi | Dyavar Principal Scientist | Adicet Bio Inc., Vilma Jimenez | Director, Quality Control and Consultant | BlueRock Therapeutics, Xiaofeng Li | Principal Scientist - Chemistry, Manufacturing, and Controls and Analytical Development group | Aurion Biotech, Yu Qian | Director and Head of Analytical Project Leads and Cell Therapies | Novartis AG, Yuan Xia| Cell Therapy and Analytical Development Staff Scientist | Bayer, Zankar Desai | Assistant Director - Technical and Cell Therapy Testing Lab | Dana Farber Cancer Institute